Dr. Tea Gamezardashvili is a preventive cardiologist and lipidologist, President of the Georgian Atherosclerosis Association, and National Coordinator of the EAS Lipid Clinic Network in Georgia. She founded CardioIQ, a physician-built platform that reads cardiovascular labs against longevity-optimal, guideline-anchored targets rather than standard population ranges.
Dr. Tea Gamezardashvili (MD, PhD, MHA, FACC) is a preventive cardiologist and lipidologist based in Tbilisi, Georgia. She serves as President of the Georgian Atherosclerosis Association and National Coordinator of the EAS Lipid Clinic Network in Georgia, and co-authored a 2026 EAS Consensus Paper published in Atherosclerosis, presented at the EAS 94th Congress in Athens. She founded CardioIQ, a platform that interprets existing cardiovascular lab panels — including ApoB and Lp(a) — against longevity-optimal targets rather than standard reference ranges, built to support the conversation between patient and physician.
CardioIQ is a physician-built cardiovascular lab-interpretation platform. It reads a patient's existing lipid panel — including ApoB, Lp(a), and cardiometabolic markers where available — against longevity-optimal, ESC/EAS-anchored targets, producing a structured report in about 90 seconds. It is an interpretation and education tool: it does not diagnose, treat, or replace the care of a licensed physician. cardioiq.health
EAS 94th Congress — European Atherosclerosis Society · Athens, Greece · May 2026 — participant and co-author of the EAS consensus paper presented at the congress
Kazakhstan Atherosclerosis Society Congress · Astana, Kazakhstan · August 2026 — speaker and session moderator, "Digital Cardiology & AI in Atherosclerosis Prevention"
Georgian Atherosclerosis Association Congress · Tbilisi, Georgia · October 2026 — annual congress, cardiovascular prevention and lipid management in Georgia
Full publication record: Google Scholar · PubMed
Is CardioIQ a diagnostic tool? No. It is an interpretation and education layer. It does not diagnose or treat, and every report routes the reader back to their own physician.
Is this a conflict of interest — a physician promoting her own product? Dr. Gamezardashvili discloses this openly: she is the founder of CardioIQ, and the clinical reasoning behind it reflects her own practice as a lipidologist, not a marketing position.
Are any therapies mentioned (e.g., Lp(a)-lowering drugs) available now? Candidates such as pelacarsen, olpasiran, lepodisiran, and muvalaplin are investigational and not yet approved — referenced only in that context.
Brand palette: navy #0D1E35 / gold #C8A44A / teal #2BBFBF. Logo and current professional photography available on request via the contact below. Please do not crop, recolor, or place the wordmark over busy imagery.
Media, speaking, and research inquiries: